COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis
Background: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are two major infectious diseases posing significant public health threats, and their coinfection (aptly abbreviated COVID-TB) makes the situation worse. This study aimed to investigate the clinical features and prognosis of COVID...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.657006/full |
| _version_ | 1819114704462675968 |
|---|---|
| author | Wan-mei Song Wan-mei Song Jing-yu Zhao Qian-yun Zhang Qian-yun Zhang Si-qi Liu Si-qi Liu Xue-han Zhu Qi-qi An Qi-qi An Ting-ting Xu Shi-jin Li Shi-jin Li Jin-yue Liu Ning-ning Tao Ning-ning Tao Yao Liu Yao Liu Yi-fan Li Yi-fan Li Huai-chen Li Huai-chen Li Huai-chen Li |
| author_facet | Wan-mei Song Wan-mei Song Jing-yu Zhao Qian-yun Zhang Qian-yun Zhang Si-qi Liu Si-qi Liu Xue-han Zhu Qi-qi An Qi-qi An Ting-ting Xu Shi-jin Li Shi-jin Li Jin-yue Liu Ning-ning Tao Ning-ning Tao Yao Liu Yao Liu Yi-fan Li Yi-fan Li Huai-chen Li Huai-chen Li Huai-chen Li |
| author_sort | Wan-mei Song |
| collection | DOAJ |
| description | Background: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are two major infectious diseases posing significant public health threats, and their coinfection (aptly abbreviated COVID-TB) makes the situation worse. This study aimed to investigate the clinical features and prognosis of COVID-TB cases.Methods: The PubMed, Embase, Cochrane, CNKI, and Wanfang databases were searched for relevant studies published through December 18, 2020. An overview of COVID-TB case reports/case series was prepared that described their clinical characteristics and differences between survivors and deceased patients. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) for death or severe COVID-19 were calculated. The quality of outcomes was assessed using GRADEpro.Results: Thirty-six studies were included. Of 89 COVID-TB patients, 19 (23.46%) died, and 72 (80.90%) were male. The median age of non-survivors (53.95 ± 19.78 years) was greater than that of survivors (37.76 ± 15.54 years) (p < 0.001). Non-survivors were more likely to have hypertension (47.06 vs. 17.95%) or symptoms of dyspnea (72.73% vs. 30%) or bilateral lesions (73.68 vs. 47.14%), infiltrates (57.89 vs. 24.29%), tree in bud (10.53% vs. 0%), or a higher leucocyte count (12.9 [10.5–16.73] vs. 8.015 [4.8–8.97] × 109/L) than survivors (p < 0.05). In terms of treatment, 88.52% received anti-TB therapy, 50.82% received antibiotics, 22.95% received antiviral therapy, 26.23% received hydroxychloroquine, and 11.48% received corticosteroids. The pooled ORs of death or severe disease in the COVID-TB group and the non-TB group were 2.21 (95% CI: 1.80, 2.70) and 2.77 (95% CI: 1.33, 5.74) (P < 0.01), respectively.Conclusion: In summary, there appear to be some predictors of worse prognosis among COVID-TB cases. A moderate level of evidence suggests that COVID-TB patients are more likely to suffer severe disease or death than COVID-19 patients. Finally, routine screening for TB may be recommended among suspected or confirmed cases of COVID-19 in countries with high TB burden. |
| first_indexed | 2024-12-22T04:49:32Z |
| format | Article |
| id | doaj.art-bf48cd0d7f594b4bb08210aa53686a76 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-22T04:49:32Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-bf48cd0d7f594b4bb08210aa53686a762022-12-21T18:38:31ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.657006657006COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-AnalysisWan-mei Song0Wan-mei Song1Jing-yu Zhao2Qian-yun Zhang3Qian-yun Zhang4Si-qi Liu5Si-qi Liu6Xue-han Zhu7Qi-qi An8Qi-qi An9Ting-ting Xu10Shi-jin Li11Shi-jin Li12Jin-yue Liu13Ning-ning Tao14Ning-ning Tao15Yao Liu16Yao Liu17Yi-fan Li18Yi-fan Li19Huai-chen Li20Huai-chen Li21Huai-chen Li22Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaCheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Geriatrics, People Hospital of Dongying District, Dongying, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaCheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaCheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaCheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaCheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Critical Care Medicine, Shandong Provincial Third Hospital, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Beijing Hospital, Beijing, ChinaGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaDepartment of Geriatrics, People Hospital of Dongying District, Dongying, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, ChinaDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, ChinaFirst College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaBackground: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are two major infectious diseases posing significant public health threats, and their coinfection (aptly abbreviated COVID-TB) makes the situation worse. This study aimed to investigate the clinical features and prognosis of COVID-TB cases.Methods: The PubMed, Embase, Cochrane, CNKI, and Wanfang databases were searched for relevant studies published through December 18, 2020. An overview of COVID-TB case reports/case series was prepared that described their clinical characteristics and differences between survivors and deceased patients. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) for death or severe COVID-19 were calculated. The quality of outcomes was assessed using GRADEpro.Results: Thirty-six studies were included. Of 89 COVID-TB patients, 19 (23.46%) died, and 72 (80.90%) were male. The median age of non-survivors (53.95 ± 19.78 years) was greater than that of survivors (37.76 ± 15.54 years) (p < 0.001). Non-survivors were more likely to have hypertension (47.06 vs. 17.95%) or symptoms of dyspnea (72.73% vs. 30%) or bilateral lesions (73.68 vs. 47.14%), infiltrates (57.89 vs. 24.29%), tree in bud (10.53% vs. 0%), or a higher leucocyte count (12.9 [10.5–16.73] vs. 8.015 [4.8–8.97] × 109/L) than survivors (p < 0.05). In terms of treatment, 88.52% received anti-TB therapy, 50.82% received antibiotics, 22.95% received antiviral therapy, 26.23% received hydroxychloroquine, and 11.48% received corticosteroids. The pooled ORs of death or severe disease in the COVID-TB group and the non-TB group were 2.21 (95% CI: 1.80, 2.70) and 2.77 (95% CI: 1.33, 5.74) (P < 0.01), respectively.Conclusion: In summary, there appear to be some predictors of worse prognosis among COVID-TB cases. A moderate level of evidence suggests that COVID-TB patients are more likely to suffer severe disease or death than COVID-19 patients. Finally, routine screening for TB may be recommended among suspected or confirmed cases of COVID-19 in countries with high TB burden.https://www.frontiersin.org/articles/10.3389/fmed.2021.657006/fullCOVID-19tuberculosisco-infectionclinical featuresrisk factors |
| spellingShingle | Wan-mei Song Wan-mei Song Jing-yu Zhao Qian-yun Zhang Qian-yun Zhang Si-qi Liu Si-qi Liu Xue-han Zhu Qi-qi An Qi-qi An Ting-ting Xu Shi-jin Li Shi-jin Li Jin-yue Liu Ning-ning Tao Ning-ning Tao Yao Liu Yao Liu Yi-fan Li Yi-fan Li Huai-chen Li Huai-chen Li Huai-chen Li COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis Frontiers in Medicine COVID-19 tuberculosis co-infection clinical features risk factors |
| title | COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis |
| title_full | COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis |
| title_fullStr | COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis |
| title_full_unstemmed | COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis |
| title_short | COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis |
| title_sort | covid 19 and tuberculosis coinfection an overview of case reports case series and meta analysis |
| topic | COVID-19 tuberculosis co-infection clinical features risk factors |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2021.657006/full |
| work_keys_str_mv | AT wanmeisong covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT wanmeisong covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT jingyuzhao covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT qianyunzhang covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT qianyunzhang covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT siqiliu covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT siqiliu covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT xuehanzhu covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT qiqian covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT qiqian covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT tingtingxu covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT shijinli covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT shijinli covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT jinyueliu covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT ningningtao covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT ningningtao covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT yaoliu covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT yaoliu covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT yifanli covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT yifanli covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT huaichenli covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT huaichenli covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis AT huaichenli covid19andtuberculosiscoinfectionanoverviewofcasereportscaseseriesandmetaanalysis |